Nanotechnology Now - Press Release: "pSivida to Present at the Astrologers Fund Conference in New York City"

Home > Press > pSivida to Present at the Astrologers Fund Conference in New York City

Abstract:
Global drug delivery company, pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that the Company's Vice President, Investor Relations, Mr Brian Leedman, will be making a company presentation at the Astrologers Fund Conference for Emerging Hi-Growth Sectors at the Princeton Club, NYC, 1pm US EST on Tuesday, September 11th, 2007. The Company will be providing an update on the recent activities and goals moving forward.

pSivida to Present at the Astrologers Fund Conference in New York City

BOSTON & PERTH, Australia | Posted on September 10th, 2007

The Astrologers Fund Hi-Growth Sectors Conference features emerging and quality investment opportunities in attractive small, mid and microcap companies. Details about this conference can be obtained by going to the website link below:

http://www.afund.com/fallinvest2007.html

The Company's presentation will not be webcast but can be viewed at the website link below:

http://www.psivida.com/News/Presentations.asp

####

About pSivida Limited
pSivida is a global drug delivery company committed to the biomedical sector and the development of drug delivery products. Retisert® is FDA approved for the treatment of uveitis. Vitrasert® is FDA approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb owns the trademarks Vitrasert® and Retisert®. pSivida has licensed the technologies underlying both of these products to Bausch & Lomb. The technology underlying Medidur™ for diabetic macular edema is licensed to Alimera Sciences and is in Phase III clinical trials. pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. for other ophthalmic applications of the Medidur™ technology.

pSivida owns the rights to develop and commercialize a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon™, which has applications in drug delivery, wound healing, orthopedics, and tissue engineering. The most advanced BioSilicon™ product, BrachySil™ delivers a therapeutic, P32 directly to solid tumors and is presently in Phase II clinical trials for the treatment of pancreatic cancer.

pSivida’s intellectual property portfolio consists of 71 patent families, 99 granted patents, including patents accepted for issuance, and over 300 patent applications. pSivida conducts its operations from facilities near Boston in the United States, Malvern in the United Kingdom and Perth in Australia.

pSivida is listed on NASDAQ (PSDV), the Australian Stock Exchange (PSD) and on the Frankfurt Stock Exchange on the XETRA system (PSI). pSivida is a founding member of the NASDAQ Health Care Index and the Merrill Lynch Nanotechnology Index.

This release contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors that are contained in cautionary statements in the Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida.

Contacts:
pSivida Limited
Brian Leedman
Vice President, Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099

or
US Public Relations
Beverly Jedynak
President
Martin E. Janis & Company, Inc
Tel: +1 (312) 943 1123

or
European Public Relations
Eva Reuter
Accent Marketing Limited
Tel: +49 (254) 393 0740